Home/Pipeline/itNSCs

itNSCs

Spinal Cord Injury

DevelopmentActive

Key Facts

Indication

Spinal Cord Injury

Phase

Development

Status

Active

Company

Stemedica Cell Technologies

About Stemedica Cell Technologies

Stemedica is a private, clinical-stage biotech company specializing in allogeneic progenitor cell therapies manufactured using its proprietary low-oxygen BioSmart Technology™ platform. The company's pipeline is anchored by ischemia-tolerant mesenchymal stem cells (itMSCs) in Phase IIb/III trials for chronic ischemic stroke and earlier development for Alzheimer's, alongside ischemia-tolerant neural progenitor cells (itNSCs) for spinal cord injury. With a cGMP-licensed manufacturing facility and a robust IP portfolio, Stemedica aims to address significant unmet needs in neurology, though it faces the inherent risks of clinical development and a competitive cell therapy landscape.

View full company profile

Therapeutic Areas

Neurology Cardiovascular

Other Spinal Cord Injury Drugs

Drug	Company	Phase	Status
MSC‑SCI	Advancells	Phase 1	Active
MAP4343	Mapreg	Preclinical	Active
Spinal Cord Injury Program	BioAxone Biosciences	Clinical	Active
Undisclosed Scaffold Program	Innervace	Pre-clinical	Active
Q-Cells	Q Therapeutics	Research	Active
APOSEC	Aposcience	Pre-clinical	Active
NG004	Neurimmune	Phase 1	Active
Perineline™	NeuroSolv Therapeutics	Phase 1	Active
Nogo-A Receptor Blocking Antibody	NovaGo Therapeutics	Phase 1b	Active
Spinal Cord Injury (SCI) Neural Bridge	Matricelf	Preclinical	Active